



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Tuesday, November 24, 2009

ChemoCentryx, Inc.

[View the current ChemoCentryx, Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx%2C+Inc..html)

(<http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx%2C+Inc..html>)

Contact Details:

**850 Maude Avenue
Mountain View
California
94043
United States of America**

Tel: 650-210-2900
Fax: 650-210-2910
Email:

ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for autoimmune diseases, inflammatory disorders and oncology.

By leveraging our pioneering expertise in the field of chemokine research, ChemoCentryx has generated a broad portfolio of medicines targeting the chemokine system, with six product candidates currently in pre-clinical and clinical stages of development. Our pipeline includes: Traficet-EN™ currently in Phase II clinical studies and initially being developed for inflammatory bowel disease. Traficet-EN targets a chemokine receptor called CCR9, which regulates the trafficking of inflammatory cells to the digestive tract. In a separate program, ChemoCentryx intends to take a new drug candidate for multiple sclerosis and cardiovascular disease, targeting the receptor CCR2, into clinical trials this year. Also, two promising compounds targeting novel chemokine receptors are in development for the treatment of cancers. Lastly, ChemoCentryx has two partnered programs. A CCR1 antagonist is being co-developed with Forest Laboratories for autoimmune disorders and CXCR3 receptor antagonists are being developed by ChemoCentryx's partner, Amgen-SF (formerly Tularik).

Press Releases on ChemoCentryx, Inc.:

[PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN\(TM\) Presented in Oral Session at DDW 2009 Conference](#)

1st June, 2009

ChemoCentryx, Inc.

Oral CCR9 Antagonist Demonstrates Clinical Efficacy with Favorable Tolerability Profile MOUNTAIN VIEW, Calif., June 1 /PRNewswire/ -- ChemoCentryx, Inc., announced that Phase II/III clinical data

[ChemoCentryx's
Traficet-EN\(TM\) Phase II/III
Induction Phase Data in
Crohn's Disease to be
Featured in Oral Presentation at
2009 Digestive Disease Week](#)

19th May, 2009

ChemoCentryx, Inc.

*First-in-class Oral
Therapeutic for IBD with
Novel Mode of Action
MOUNTAIN VIEW, Calif.,
May 19 /PRNewswire/ --
ChemoCentryx, Inc., today
announced that data from
the company's
PROTECT-1 (the*

[ChemoCentryx Identifies Novel
Small Molecule C5aR Antagonist](#)

5th May, 2009

ChemoCentryx, Inc.

*Development Candidate
Triggers Milestone
Payment from
GlaxoSmithKline
MOUNTAIN VIEW, Calif.,
May 5 /PRNewswire/ --
ChemoCentryx, Inc., today
announced that it has
identified an orally*

[Solexa Names Linda Rubinstein
Vice President And CFO](#)

1st January, 1970 Solexa

*Solexa Names Linda
Rubinstein Vice President
And CFO HAYWARD,
Calif. (March 30, 2005) –
Solexa, Inc. (NASDAQ:
SLXA) today announced the*

BioNews Results for ChemoCentryx, Inc.



- [Guru Stocks at 52-Week Low: Genzyme Corp, Apollo Group Inc, Ralcorp Holdings Inc, Aqua America Inc, MetroPCS C](#)
Guru Focus: Nov 16 2009 3:51AM Matching: inc
- [AngioDynamics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released](#)
PR inside: Nov 16 2009 5:28AM Matching: inc
- [Antares Pharma, Inc. - Medical Equipment - Deals and Alliances Profile - new report released](#)
PR inside: Nov 16 2009 5:23AM Matching: inc
- [Antares Pharma, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report](#)
PR inside: Nov 16 2009 5:23AM Matching: inc
- [AspenBio Pharma, Inc. - Medical Equipment - Deals and Alliances Profile - new report released](#)
PR inside: Nov 16 2009 4:58AM Matching: inc
- [BELLUS Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report](#)
PR inside: Nov 16 2009 4:26AM Matching: inc
- [BELLUS Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report](#)
PR inside: Nov 16 2009 4:26AM Matching: inc
- [J.C. Penney, Disney, Genzyme are big movers](#)
Austin American Statesman: Nov 15 2009 1:20PM Matching: inc

- [UPDATING and REPLACING -- GeoPharma Announces Fiscal Year 2010 Second Quarter Results Release Date and Confere](#)
Presentation Master: Nov 15 2009 12:49AM Matching: inc
- [GeoPharma Announces Fiscal Year 2010 Second Quarter Results Release Date and Conference Call](#)
Presentation Master: Nov 15 2009 12:48AM Matching: inc
- [J.C. Penney, Disney, Genzyme are big movers](#)
Crescent-News: Nov 15 2009 12:29AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
World Market Media: Nov 14 2009 11:33PM Matching: inc
- [Our Members Know First!! PSGI-'Prime Star Group Introduces Delizia Limited Cigars' Sign Up Today!!](#)
Pharmacy Choice: Nov 14 2009 12:56AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
Review Seeker: Nov 14 2009 9:41AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
RBC Dain Rauscher: Nov 14 2009 4:53AM Matching: inc

ChemoCentryx, Inc. Patents:



- 7589199- [Substituted piperazines](#)
- 7335653- [Bis-aryl sulfonamides](#)
- 7282338- [Cell migration assay](#)
- 7262204- [Modulation of CCR4 function](#)
- 7253007- [Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors](#)
- 7157464- [Substituted piperazines](#)
- 7108990- [Chemokine receptor](#)
- 7101894- [Bicyclic compounds as inhibitors of chemokine binding to US28](#)
- 7025968- [CMV vaccines](#)
- 6998239- [Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine](#)
- 6992084- [Compounds and methods for modulating CXCR3 function](#)
- 6835547- [Methods for identifying modulators of CCX CKR activity](#)
- 6821998- [Arylamines as inhibitors of chemokine binding to US28](#)
- 6740324- [Methods and compositions useful for stimulating an immune response](#)
- 6699677- [Tethered ligands and methods of use](#)
- 7361329- [Compositions for inducing an immune response](#)
- 7396653- [Cell migration assay](#)
- 7582661- [Aryl sulfonamides](#)
- 7576218- [4-phenylpiperidine-pyrazole CCR1 antagonists](#)
- 7576106- [Piperidine derivatives and methods of use](#)
- 7572600- [Enzymatic activities in chemokine-mediated inflammation](#)
- 7557213- [Substituted quinolones and methods of use](#)
- 7524845- [Azaindazole compounds and methods of use](#)
- 7468253- [Method for multiple chemokine receptor screening for antagonists using RAM assay](#)
- 7449576- [Substituted piperazines](#)

- 7442512- [Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors](#)
- 7435831- [Bicyclic and bridged nitrogen heterocycles](#)
- 7435830- [Bicyclic and bridged nitrogen heterocycles](#)
- 7420055- [Aryl sulfonamides](#)
- 7417062- [Substituted arylamides](#)
- 7413866- [Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors](#)
- 6559160- [Compounds and methods for modulating cxcr3 function](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

